Effect of oseltamivir treatment on anticoagulation: A cross-over study in warfarinized patients

British Journal of Clinical Pharmacology

Volumn 70, Issue 6, 2010, Pages 834-843

  Davies, Brian E ^a   Baldó, Pau Aceves ^b   Lennon Chrimes, Sian ^b   Brewster, Mike ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Coagulation; Interaction; Oseltamivir; Pharmacodynamics; Pharmacokinetics; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 7A; OSELTAMIVIR; VASODILATOR AGENT; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFECT; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MALE; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; URINALYSIS; VASCULAR DISEASE; VITAL SIGN;

AGED; ANTICOAGULANTS; ANTIVIRAL AGENTS; BLOOD COAGULATION; CROSS-OVER STUDIES; DRUG INTERACTIONS; FACTOR VIIA; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; OSELTAMIVIR; VITAMIN K 1; WARFARIN;

EID: 78349265411     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03780.x     Document Type: Article

References (18)

1. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31: 1097-114.
2. Roche. Tamiflu: summary of main product characteristics. electronic Medicines Compendium (eMC). 17-2-2009.
3. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003; 26: 787-801.
4. Pepper S, Murty H. Oseltamivir (Tamiflu) and warfarin: suspected increase in INR. Canadian Adverse Reaction Newsletter 2006; 16: 1-2.
5. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471-84.
6. Paliani U, Filippucci E, Gresele P. Significant potentiation of anticoagulation by flu-vaccine during the season 2001-2002. Haematologica 2003; 88: 599-600.
7. Lipsky BA, Pecoraro RE, Roben NJ, De BP, Delaney CJ. Influenza vaccination and warfarin anticoagulation. Ann Intern Med 1984; 100: 835-7.
8. Gomolin IH, Chapron DJ, Luhan PA. Lack of effect of influenza vaccine on theophylline levels and warfarin anticoagulation in the elderly. J Am Geriatr Soc 1985; 33: 269-72.
9. Bussey HI, Saklad JJ. Effect of influenza vaccine on chronic warfarin therapy. Drug Intell Clin Pharm 1988; 22: 198-201.
10. Raj G, Kumar R, McKinney WP. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy. Arch Intern Med 1995; 155: 1529-31.
11. Sumner HW, Holtzman JL, McClain CJ. Drug-induced liver disease. Geriatrics 1981; 36: 83-96.
12. Kramer P, Tsuru M, Cook CE, McClain CJ, Holtzman JL. Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther 1984; 35: 416-8.
13. Beeley L, Cunningham H, Carmichael A, Brennan A. Bulletin for the West Midland Centre for Adverse Drug Reaction Reporting. 1991; 33: 19.
14. Carroll DN, Carroll DG. Fatal intracranial bleed potentially due to a warfarin and influenza vaccine interaction. Ann Pharmacother 2009; 43: 754-60.
15. Ward P, Massarella J, Dorr A, Ipe D. Clinical Study Report- Protocol NP15717. Study of the pharmacodynamics and pharmacokinetics of the neuraminidase inhibitor oseltamivir (GS4104) in the treatment of volunteers experimentally infected with human influenza B virus. Research Report No. W-144105, 1999 (Roche, data on file).
16. Davies B, Huson L. Clinical Study Report- Protocol WP20727. A single ascending dose and exploratory bioavailability study to investigate the safety, tolerability and pharmacokinetics of intravenous Ro 64-0796 in healthy volunteers. Research Report No. 1030591, 1997 (Roche, data on file).
17. Schentag JJ, Hill G, Chu T, Rayner C. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol 2007; 47: 689-96.
18. Oo C, Barrett J, Dorr A, Liu B, Ward P. Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin. Antimicrob Agents Chemother 2002; 46: 1993-5.